MARKSANS PHARMA LIMITED
MARKSANS · Pharma · NSE
₹193
Current Market Price
Fair Value (DCF)
₹300
Margin of Safety
+55.2%
Updated 5h ago
YieldIQ Score
70/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
50%
ROE
—
Debt/Equity
0.12
WACC
9.7%
Market Cap
₹8,757 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.7%
Return on capital employed
EV / EBITDA
15.9×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
44.2×
EBIT covers interest
Current Ratio
4.62×
Short-term liquidity
Asset Turnover
0.81×
Revenue per ₹ of assets
Revenue CAGR (3Y)
20.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹193.25
Bear case
₹163.03
MoS -18.5%
Base case
₹299.86
MoS +35.6%
Bull case
₹363.2
MoS +46.8%
Ratio Trends
MARKSANS · last 8 annual periods
ROE
15.3%
ROCE
21.3%
Operating Margin
—
Debt / Equity
0.13×
PE
38.6×
EV / EBITDA
7.2×
Historical Financials
MARKSANS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1376 Cr | ₹1491 Cr | ₹486 Cr | ₹560 Cr | ₹2614 Cr | +17.4% |
| EBITDA | — | ₹298 Cr | ₹395 Cr | ₹509 Cr | ₹599 Cr | +19.1% |
| EBIT | ₹310 Cr | ₹256 Cr | ₹107 Cr | ₹105 Cr | — | -23.7% |
| PAT | ₹239 Cr | ₹187 Cr | ₹82.7 Cr | ₹77.6 Cr | ₹381 Cr | +12.4% |
| EPS (diluted) | ₹5.76 | ₹4.51 | ₹1.97 | ₹1.73 | — | -26.0% |
| CFO | ₹179 Cr | ₹99.3 Cr | ₹237 Cr | ₹230 Cr | ₹207 Cr | +3.7% |
| CapEx | — | — | — | — | ₹-173 Cr | — |
| FCF | — | — | — | — | ₹33.7 Cr | +0.0% |
| Total Assets | — | ₹1640 Cr | ₹2190 Cr | ₹2681 Cr | ₹3240 Cr | +18.6% |
| Total Debt | — | — | ₹41.6 Cr | ₹29.1 Cr | ₹322 Cr | +66.8% |
| Shareholders' Equity | — | — | ₹1745 Cr | ₹2065 Cr | ₹2489 Cr | +9.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MARKSANS vs 3 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SANOFI SANOFI | — | — | Pending | 43.6% | — |
| SANOFICONR Sanofi Consumer Healthcare India Limited | -41.8% | 28 | Overvalued | 62.5% | — |
| RUBICON RUBICON | — | — | Pending | — | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for MARKSANS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. MARKSANS PHARMA LIMITED (MARKSANS.NS) trades at 193.25 vs a model fair value of 299.86, a gap of 55.2%. Piotroski F-score: 5/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MARKSANS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MARKSANS →
Compare
Head-to-head with peers
Compare MARKSANS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MARKSANSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.